Osteopenia in Patients with Glomerular Diseases Requiring Long-Term Corticosteroid Therapy

Background: Chronic corticosteroid (CS) use is associated with bone mass loss. Methods: Bone mineral density (BMD) was assessed in 72 patients (25 males/47 premenopausal females) with glomerular diseases, primary (n = 35) or secondary to systemic lupus erythematosus (n = 37) with normal renal functi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nephron 2003-07, Vol.94 (3), p.c69-c74
Hauptverfasser: Barbosa de Deus, Rogério, Conde Ferreira, Alessandra, Mastroianni Kirsztajn, Gianna, Pfeferman Heilberg, Ita
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page c74
container_issue 3
container_start_page c69
container_title Nephron
container_volume 94
creator Barbosa de Deus, Rogério
Conde Ferreira, Alessandra
Mastroianni Kirsztajn, Gianna
Pfeferman Heilberg, Ita
description Background: Chronic corticosteroid (CS) use is associated with bone mass loss. Methods: Bone mineral density (BMD) was assessed in 72 patients (25 males/47 premenopausal females) with glomerular diseases, primary (n = 35) or secondary to systemic lupus erythematosus (n = 37) with normal renal function, who were taking CS, as prednisone and/or methylprednisolone, in doses ≧7.5 mg/day, for a period of at least 6 months. Cumulative dose and duration of prior CS therapy, as well as biochemical parameters and other factors contributing to bone loss were evaluated. Results: We found 37 (52%) patients with low BMD (29 with osteopenia and 8 with osteoporosis). The low BMD group presented a lower mean weight and body mass index (BMI) versus the normal BMD group (62 ± 15 vs. 70 ± 10 kg and 25 ± 4 vs. 27 ± 5, mean ± SD, p < 0.05). The estimated calcium intake was lower than 400 mg/day in all patients with low BMD, and they had taken furosemide as a concomitant drug for a longer mean period of time when compared to normal BMDpatients (30 ± 29 vs. 16 ± 27 months, p < 0.05). A higher mean number of pulses per patient and mean cumulative dose of methylprednisolone were observed in the low versus normal BMD group (7.7 ± 4.0 vs. 5.6 ± 4.0 pulses and 6.5 ± 3.9 vs. 3.9 ± 2.7 g, p < 0.05). Conclusions: These findings suggest a high frequency of osteopenia among young and premenopausal patients with glomerular diseases given long-term corticosteroid therapy. The lower BMI and calcium intake, as well as the concomitant furosemide use, might have contributed to such a bone loss. The higher number of pulse therapies leading to higher cumulative intravenous doses of corticosteroid mainly in lupus nephritis patients shows that pulse therapy may be deleterious to bone.
doi_str_mv 10.1159/000072023
format Article
fullrecord <record><control><sourceid>proquest_pasca</sourceid><recordid>TN_cdi_proquest_miscellaneous_20906132</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20906132</sourcerecordid><originalsourceid>FETCH-LOGICAL-c416t-eb6d831bc5aa000a91375d5855101a2ee968a5c1c957a020d9521ed788077d833</originalsourceid><addsrcrecordid>eNpt0MFrFDEUBvAgil2rB8-CBEHBw2heZpNMjmVta2GxpawXL8PbzNtt6sxkmswg_e8b3aUL0lxC4JeXLx9jb0F8AVD2q8jLSCHLZ2wGWotCAojnbCaErApptD5ir1K6zUcJwr5kRyCtkLosZ-zXZRopDNR75L7nVzh66sfE__jxhp-3oaM4tRj5N58IEyV-TXeTj77f8mXot8WKYscXIY7ehTwpBt_w1Q1FHO5fsxcbbBO92e_H7OfZ6WrxvVhenl8sTpaFm4MeC1rrpiph7RRi_gdaKI1qVKUUCEBJZHWFyoGzyqCQorFKAjWmqoQx-WZ5zD7t5g4x3E2UxrrzyVHbYk9hSrUUVmgoZYYf_oO3YYp9zlZLM58DlGAz-rxDLoaUIm3qIfoO430Nov7bdv3Ydrbv9wOndUfNQe7rzeDjHmBy2G4i9s6ng1NiXmpjDsl-Y9xSfAQ_Thf_XqqHZpPRuyfRLssDDcSZpQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>274411319</pqid></control><display><type>article</type><title>Osteopenia in Patients with Glomerular Diseases Requiring Long-Term Corticosteroid Therapy</title><source>MEDLINE</source><source>Karger Journals</source><creator>Barbosa de Deus, Rogério ; Conde Ferreira, Alessandra ; Mastroianni Kirsztajn, Gianna ; Pfeferman Heilberg, Ita</creator><creatorcontrib>Barbosa de Deus, Rogério ; Conde Ferreira, Alessandra ; Mastroianni Kirsztajn, Gianna ; Pfeferman Heilberg, Ita</creatorcontrib><description>Background: Chronic corticosteroid (CS) use is associated with bone mass loss. Methods: Bone mineral density (BMD) was assessed in 72 patients (25 males/47 premenopausal females) with glomerular diseases, primary (n = 35) or secondary to systemic lupus erythematosus (n = 37) with normal renal function, who were taking CS, as prednisone and/or methylprednisolone, in doses ≧7.5 mg/day, for a period of at least 6 months. Cumulative dose and duration of prior CS therapy, as well as biochemical parameters and other factors contributing to bone loss were evaluated. Results: We found 37 (52%) patients with low BMD (29 with osteopenia and 8 with osteoporosis). The low BMD group presented a lower mean weight and body mass index (BMI) versus the normal BMD group (62 ± 15 vs. 70 ± 10 kg and 25 ± 4 vs. 27 ± 5, mean ± SD, p &lt; 0.05). The estimated calcium intake was lower than 400 mg/day in all patients with low BMD, and they had taken furosemide as a concomitant drug for a longer mean period of time when compared to normal BMDpatients (30 ± 29 vs. 16 ± 27 months, p &lt; 0.05). A higher mean number of pulses per patient and mean cumulative dose of methylprednisolone were observed in the low versus normal BMD group (7.7 ± 4.0 vs. 5.6 ± 4.0 pulses and 6.5 ± 3.9 vs. 3.9 ± 2.7 g, p &lt; 0.05). Conclusions: These findings suggest a high frequency of osteopenia among young and premenopausal patients with glomerular diseases given long-term corticosteroid therapy. The lower BMI and calcium intake, as well as the concomitant furosemide use, might have contributed to such a bone loss. The higher number of pulse therapies leading to higher cumulative intravenous doses of corticosteroid mainly in lupus nephritis patients shows that pulse therapy may be deleterious to bone.</description><identifier>ISSN: 0028-2766</identifier><identifier>ISSN: 1660-2110</identifier><identifier>ISSN: 1660-8151</identifier><identifier>EISSN: 1660-2110</identifier><identifier>EISSN: 2235-3186</identifier><identifier>DOI: 10.1159/000072023</identifier><identifier>PMID: 12902633</identifier><identifier>CODEN: NPRNAY</identifier><language>eng</language><publisher>Basel, Switzerland: Karger</publisher><subject>Adrenal Cortex Hormones - adverse effects ; Adrenal Cortex Hormones - therapeutic use ; Adult ; Anti-Inflammatory Agents - administration &amp; dosage ; Anti-Inflammatory Agents - adverse effects ; Anti-Inflammatory Agents - therapeutic use ; Biological and medical sciences ; Bone Density - drug effects ; Bone Diseases, Metabolic - blood ; Bone Diseases, Metabolic - chemically induced ; Calcium - blood ; Calcium - metabolism ; Drug Administration Schedule ; Drug toxicity and drugs side effects treatment ; Female ; Femur Neck - chemistry ; Femur Neck - drug effects ; Femur Neck - pathology ; Humans ; Infusions, Intravenous ; Kidney Diseases - blood ; Kidney Diseases - drug therapy ; Kidney Diseases - etiology ; Lumbar Vertebrae - chemistry ; Lumbar Vertebrae - drug effects ; Lumbar Vertebrae - pathology ; Lupus Erythematosus, Systemic - complications ; Lupus Erythematosus, Systemic - pathology ; Male ; Medical sciences ; Methylprednisolone - administration &amp; dosage ; Methylprednisolone - adverse effects ; Methylprednisolone - therapeutic use ; Original Paper ; Pharmacology. Drug treatments ; Prednisone - administration &amp; dosage ; Prednisone - adverse effects ; Prednisone - therapeutic use ; Pulse Therapy, Drug - adverse effects ; Pulse Therapy, Drug - methods ; Toxicity: osteoarticular system</subject><ispartof>Nephron, 2003-07, Vol.94 (3), p.c69-c74</ispartof><rights>2003 S. Karger AG, Basel</rights><rights>2004 INIST-CNRS</rights><rights>Copyright 2003 S. Karger AG, Basel</rights><rights>Copyright S. Karger AG Jul 2003</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c416t-eb6d831bc5aa000a91375d5855101a2ee968a5c1c957a020d9521ed788077d833</citedby><cites>FETCH-LOGICAL-c416t-eb6d831bc5aa000a91375d5855101a2ee968a5c1c957a020d9521ed788077d833</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,2423,27905,27906</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=15043677$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12902633$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Barbosa de Deus, Rogério</creatorcontrib><creatorcontrib>Conde Ferreira, Alessandra</creatorcontrib><creatorcontrib>Mastroianni Kirsztajn, Gianna</creatorcontrib><creatorcontrib>Pfeferman Heilberg, Ita</creatorcontrib><title>Osteopenia in Patients with Glomerular Diseases Requiring Long-Term Corticosteroid Therapy</title><title>Nephron</title><addtitle>Nephron Clin Pract</addtitle><description>Background: Chronic corticosteroid (CS) use is associated with bone mass loss. Methods: Bone mineral density (BMD) was assessed in 72 patients (25 males/47 premenopausal females) with glomerular diseases, primary (n = 35) or secondary to systemic lupus erythematosus (n = 37) with normal renal function, who were taking CS, as prednisone and/or methylprednisolone, in doses ≧7.5 mg/day, for a period of at least 6 months. Cumulative dose and duration of prior CS therapy, as well as biochemical parameters and other factors contributing to bone loss were evaluated. Results: We found 37 (52%) patients with low BMD (29 with osteopenia and 8 with osteoporosis). The low BMD group presented a lower mean weight and body mass index (BMI) versus the normal BMD group (62 ± 15 vs. 70 ± 10 kg and 25 ± 4 vs. 27 ± 5, mean ± SD, p &lt; 0.05). The estimated calcium intake was lower than 400 mg/day in all patients with low BMD, and they had taken furosemide as a concomitant drug for a longer mean period of time when compared to normal BMDpatients (30 ± 29 vs. 16 ± 27 months, p &lt; 0.05). A higher mean number of pulses per patient and mean cumulative dose of methylprednisolone were observed in the low versus normal BMD group (7.7 ± 4.0 vs. 5.6 ± 4.0 pulses and 6.5 ± 3.9 vs. 3.9 ± 2.7 g, p &lt; 0.05). Conclusions: These findings suggest a high frequency of osteopenia among young and premenopausal patients with glomerular diseases given long-term corticosteroid therapy. The lower BMI and calcium intake, as well as the concomitant furosemide use, might have contributed to such a bone loss. The higher number of pulse therapies leading to higher cumulative intravenous doses of corticosteroid mainly in lupus nephritis patients shows that pulse therapy may be deleterious to bone.</description><subject>Adrenal Cortex Hormones - adverse effects</subject><subject>Adrenal Cortex Hormones - therapeutic use</subject><subject>Adult</subject><subject>Anti-Inflammatory Agents - administration &amp; dosage</subject><subject>Anti-Inflammatory Agents - adverse effects</subject><subject>Anti-Inflammatory Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Bone Density - drug effects</subject><subject>Bone Diseases, Metabolic - blood</subject><subject>Bone Diseases, Metabolic - chemically induced</subject><subject>Calcium - blood</subject><subject>Calcium - metabolism</subject><subject>Drug Administration Schedule</subject><subject>Drug toxicity and drugs side effects treatment</subject><subject>Female</subject><subject>Femur Neck - chemistry</subject><subject>Femur Neck - drug effects</subject><subject>Femur Neck - pathology</subject><subject>Humans</subject><subject>Infusions, Intravenous</subject><subject>Kidney Diseases - blood</subject><subject>Kidney Diseases - drug therapy</subject><subject>Kidney Diseases - etiology</subject><subject>Lumbar Vertebrae - chemistry</subject><subject>Lumbar Vertebrae - drug effects</subject><subject>Lumbar Vertebrae - pathology</subject><subject>Lupus Erythematosus, Systemic - complications</subject><subject>Lupus Erythematosus, Systemic - pathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Methylprednisolone - administration &amp; dosage</subject><subject>Methylprednisolone - adverse effects</subject><subject>Methylprednisolone - therapeutic use</subject><subject>Original Paper</subject><subject>Pharmacology. Drug treatments</subject><subject>Prednisone - administration &amp; dosage</subject><subject>Prednisone - adverse effects</subject><subject>Prednisone - therapeutic use</subject><subject>Pulse Therapy, Drug - adverse effects</subject><subject>Pulse Therapy, Drug - methods</subject><subject>Toxicity: osteoarticular system</subject><issn>0028-2766</issn><issn>1660-2110</issn><issn>1660-8151</issn><issn>1660-2110</issn><issn>2235-3186</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpt0MFrFDEUBvAgil2rB8-CBEHBw2heZpNMjmVta2GxpawXL8PbzNtt6sxkmswg_e8b3aUL0lxC4JeXLx9jb0F8AVD2q8jLSCHLZ2wGWotCAojnbCaErApptD5ir1K6zUcJwr5kRyCtkLosZ-zXZRopDNR75L7nVzh66sfE__jxhp-3oaM4tRj5N58IEyV-TXeTj77f8mXot8WKYscXIY7ehTwpBt_w1Q1FHO5fsxcbbBO92e_H7OfZ6WrxvVhenl8sTpaFm4MeC1rrpiph7RRi_gdaKI1qVKUUCEBJZHWFyoGzyqCQorFKAjWmqoQx-WZ5zD7t5g4x3E2UxrrzyVHbYk9hSrUUVmgoZYYf_oO3YYp9zlZLM58DlGAz-rxDLoaUIm3qIfoO430Nov7bdv3Ydrbv9wOndUfNQe7rzeDjHmBy2G4i9s6ng1NiXmpjDsl-Y9xSfAQ_Thf_XqqHZpPRuyfRLssDDcSZpQ</recordid><startdate>20030701</startdate><enddate>20030701</enddate><creator>Barbosa de Deus, Rogério</creator><creator>Conde Ferreira, Alessandra</creator><creator>Mastroianni Kirsztajn, Gianna</creator><creator>Pfeferman Heilberg, Ita</creator><general>Karger</general><general>S. Karger AG</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>S0X</scope><scope>7QP</scope></search><sort><creationdate>20030701</creationdate><title>Osteopenia in Patients with Glomerular Diseases Requiring Long-Term Corticosteroid Therapy</title><author>Barbosa de Deus, Rogério ; Conde Ferreira, Alessandra ; Mastroianni Kirsztajn, Gianna ; Pfeferman Heilberg, Ita</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c416t-eb6d831bc5aa000a91375d5855101a2ee968a5c1c957a020d9521ed788077d833</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adrenal Cortex Hormones - adverse effects</topic><topic>Adrenal Cortex Hormones - therapeutic use</topic><topic>Adult</topic><topic>Anti-Inflammatory Agents - administration &amp; dosage</topic><topic>Anti-Inflammatory Agents - adverse effects</topic><topic>Anti-Inflammatory Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Bone Density - drug effects</topic><topic>Bone Diseases, Metabolic - blood</topic><topic>Bone Diseases, Metabolic - chemically induced</topic><topic>Calcium - blood</topic><topic>Calcium - metabolism</topic><topic>Drug Administration Schedule</topic><topic>Drug toxicity and drugs side effects treatment</topic><topic>Female</topic><topic>Femur Neck - chemistry</topic><topic>Femur Neck - drug effects</topic><topic>Femur Neck - pathology</topic><topic>Humans</topic><topic>Infusions, Intravenous</topic><topic>Kidney Diseases - blood</topic><topic>Kidney Diseases - drug therapy</topic><topic>Kidney Diseases - etiology</topic><topic>Lumbar Vertebrae - chemistry</topic><topic>Lumbar Vertebrae - drug effects</topic><topic>Lumbar Vertebrae - pathology</topic><topic>Lupus Erythematosus, Systemic - complications</topic><topic>Lupus Erythematosus, Systemic - pathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Methylprednisolone - administration &amp; dosage</topic><topic>Methylprednisolone - adverse effects</topic><topic>Methylprednisolone - therapeutic use</topic><topic>Original Paper</topic><topic>Pharmacology. Drug treatments</topic><topic>Prednisone - administration &amp; dosage</topic><topic>Prednisone - adverse effects</topic><topic>Prednisone - therapeutic use</topic><topic>Pulse Therapy, Drug - adverse effects</topic><topic>Pulse Therapy, Drug - methods</topic><topic>Toxicity: osteoarticular system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Barbosa de Deus, Rogério</creatorcontrib><creatorcontrib>Conde Ferreira, Alessandra</creatorcontrib><creatorcontrib>Mastroianni Kirsztajn, Gianna</creatorcontrib><creatorcontrib>Pfeferman Heilberg, Ita</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>SIRS Editorial</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><jtitle>Nephron</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Barbosa de Deus, Rogério</au><au>Conde Ferreira, Alessandra</au><au>Mastroianni Kirsztajn, Gianna</au><au>Pfeferman Heilberg, Ita</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Osteopenia in Patients with Glomerular Diseases Requiring Long-Term Corticosteroid Therapy</atitle><jtitle>Nephron</jtitle><addtitle>Nephron Clin Pract</addtitle><date>2003-07-01</date><risdate>2003</risdate><volume>94</volume><issue>3</issue><spage>c69</spage><epage>c74</epage><pages>c69-c74</pages><issn>0028-2766</issn><issn>1660-2110</issn><issn>1660-8151</issn><eissn>1660-2110</eissn><eissn>2235-3186</eissn><coden>NPRNAY</coden><abstract>Background: Chronic corticosteroid (CS) use is associated with bone mass loss. Methods: Bone mineral density (BMD) was assessed in 72 patients (25 males/47 premenopausal females) with glomerular diseases, primary (n = 35) or secondary to systemic lupus erythematosus (n = 37) with normal renal function, who were taking CS, as prednisone and/or methylprednisolone, in doses ≧7.5 mg/day, for a period of at least 6 months. Cumulative dose and duration of prior CS therapy, as well as biochemical parameters and other factors contributing to bone loss were evaluated. Results: We found 37 (52%) patients with low BMD (29 with osteopenia and 8 with osteoporosis). The low BMD group presented a lower mean weight and body mass index (BMI) versus the normal BMD group (62 ± 15 vs. 70 ± 10 kg and 25 ± 4 vs. 27 ± 5, mean ± SD, p &lt; 0.05). The estimated calcium intake was lower than 400 mg/day in all patients with low BMD, and they had taken furosemide as a concomitant drug for a longer mean period of time when compared to normal BMDpatients (30 ± 29 vs. 16 ± 27 months, p &lt; 0.05). A higher mean number of pulses per patient and mean cumulative dose of methylprednisolone were observed in the low versus normal BMD group (7.7 ± 4.0 vs. 5.6 ± 4.0 pulses and 6.5 ± 3.9 vs. 3.9 ± 2.7 g, p &lt; 0.05). Conclusions: These findings suggest a high frequency of osteopenia among young and premenopausal patients with glomerular diseases given long-term corticosteroid therapy. The lower BMI and calcium intake, as well as the concomitant furosemide use, might have contributed to such a bone loss. The higher number of pulse therapies leading to higher cumulative intravenous doses of corticosteroid mainly in lupus nephritis patients shows that pulse therapy may be deleterious to bone.</abstract><cop>Basel, Switzerland</cop><pub>Karger</pub><pmid>12902633</pmid><doi>10.1159/000072023</doi><tpages>1</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0028-2766
ispartof Nephron, 2003-07, Vol.94 (3), p.c69-c74
issn 0028-2766
1660-2110
1660-8151
1660-2110
2235-3186
language eng
recordid cdi_proquest_miscellaneous_20906132
source MEDLINE; Karger Journals
subjects Adrenal Cortex Hormones - adverse effects
Adrenal Cortex Hormones - therapeutic use
Adult
Anti-Inflammatory Agents - administration & dosage
Anti-Inflammatory Agents - adverse effects
Anti-Inflammatory Agents - therapeutic use
Biological and medical sciences
Bone Density - drug effects
Bone Diseases, Metabolic - blood
Bone Diseases, Metabolic - chemically induced
Calcium - blood
Calcium - metabolism
Drug Administration Schedule
Drug toxicity and drugs side effects treatment
Female
Femur Neck - chemistry
Femur Neck - drug effects
Femur Neck - pathology
Humans
Infusions, Intravenous
Kidney Diseases - blood
Kidney Diseases - drug therapy
Kidney Diseases - etiology
Lumbar Vertebrae - chemistry
Lumbar Vertebrae - drug effects
Lumbar Vertebrae - pathology
Lupus Erythematosus, Systemic - complications
Lupus Erythematosus, Systemic - pathology
Male
Medical sciences
Methylprednisolone - administration & dosage
Methylprednisolone - adverse effects
Methylprednisolone - therapeutic use
Original Paper
Pharmacology. Drug treatments
Prednisone - administration & dosage
Prednisone - adverse effects
Prednisone - therapeutic use
Pulse Therapy, Drug - adverse effects
Pulse Therapy, Drug - methods
Toxicity: osteoarticular system
title Osteopenia in Patients with Glomerular Diseases Requiring Long-Term Corticosteroid Therapy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T14%3A30%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Osteopenia%20in%20Patients%20with%20Glomerular%20Diseases%20Requiring%20Long-Term%20Corticosteroid%20Therapy&rft.jtitle=Nephron&rft.au=Barbosa%20de%20Deus,%20Rog%C3%A9rio&rft.date=2003-07-01&rft.volume=94&rft.issue=3&rft.spage=c69&rft.epage=c74&rft.pages=c69-c74&rft.issn=0028-2766&rft.eissn=1660-2110&rft.coden=NPRNAY&rft_id=info:doi/10.1159/000072023&rft_dat=%3Cproquest_pasca%3E20906132%3C/proquest_pasca%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=274411319&rft_id=info:pmid/12902633&rfr_iscdi=true